Rectal Gastrointestinal Stromal Tumor Poor Response to Imatinib: A Case Report
Open Access
- 25 August 2026
- journal article
- case report
- Published by Wiley in Clinical Case Reports
- Vol. 14 (9) , e73395
Abstract
A 63‐year‐old man presented with persistent constipation lasting 6.5 months. Digital rectal examination revealed a soft‐tissue lesion near the anal verge without bleeding. Further evaluation identified a rectal mass. Treatment with imatinib for 6 months showed no significant response. The patient subsequently underwent surgical resection, with favorable short‐term clinical outcomes.Keywords
This publication has 6 references indexed in Scilit:
- Efficacy and safety of neoadjuvant imatinib therapy for patients with locally advanced rectal gastrointestinal stromal tumors: A multi-center cohort studyFrontiers in Pharmacology, 2022
- Gastrointestinal stromal tumours: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2022
- The effect of neoadjuvant imatinib therapy on outcome and survival in rectal gastrointestinal stromal tumors: A multiinstitutional studyJournal of Surgical Oncology, 2021
- Transanal versus nontransanal surgery for the treatment of primary rectal gastrointestinal stromal tumors: a 10-year experience in a high-volume centerAnnals of Translational Medicine, 2020
- Gastrointestinal stromal tumors: Pathology and prognosis at different sitesSeminars in Diagnostic Pathology, 2006
- Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal TumorJournal of Clinical Oncology, 2003